Study of Tarperprumig for ANCA-associated vasculitis
Part of Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests a new drug (tarperprumig) for people with active ANCA-associated vasculitis (GPA or MPA). The goal is to see if it is safe and effective for treating the disease, especially when standard treatments like rituximab or cyclophosphamide are being considered.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of vasculitis called GPA (granulomatosis with polyangiitis) or MPA (microscopic polyangiitis) that is either newly diagnosed or has come back after treatment.
- You have tested positive for ANCA antibodies (PR3 or MPO) in the past or at the screening visit.
- You have active disease symptoms that need treatment, like significant kidney problems, lung, or other organ issues.
- You do not have other types of vasculitis or autoimmune diseases as the main cause of your illness, such as lupus, EGPA, or anti-GBM disease.
- You do not have severe lung bleeding that requires a breathing machine at the time of screening.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called NM8074 for a type of blood vessel inflammation called ANCA-associated vasculitis. It's for people whose vasculitis is active and needs a stronger treatment like cyclophosphamide or rituximab.
This Phase 3 trial studies “salvage” treatment for people with active granulomatosis with polyangiitis (GPA) whose standard treatments have not worked well enough. It aims to improve disease control and reduce the need for ongoing higher-dose steroids.
This Phase 4 trial studies whether rituximab combined with telitacicept works better and is safe for people with severe active ANCA-associated vasculitis (including certain subtypes like GPA or MPA). If you meet specific blood test and disease activity criteria, you may be considered to help lower inflammation and prevent flare-ups.
This trial studies whether extending low-dose prednisone alongside rituximab (given as infusions at set times) helps keep microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) in remission. If you respond to initial treatment, the goal is to reduce the chance of relapse and maintain disease control.
This trial tests a medication called avacopan for people with ANCA-associated vasculitis, a condition where the immune system attacks blood vessels. Avacopan is taken with standard treatments to help control the disease and may reduce the need for steroids.
This study compares two ways of managing ANCA-associated vasculitis (inflammation of blood vessels) when ANCA antibodies reappear after remission. One approach is close monitoring with blood tests, and the other is giving rituximab infusions right away to prevent a flare-up. It aims to find out which strategy better prevents disease relapse.
Hear when a new Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.